Table 4. Diagnostic efficiency of the miRNA marker panel on sputum of 64 NSCLC patients and 58 healthy subjects*.
| Sensitivity | Specificity | P | |
|---|---|---|---|
| Histological types | All <0.05 | ||
| AC | 80.60% | 92.50% | |
| SC | 64.10% | 71.30% | |
| Tumor location | All <0.05 | ||
| Peripheral tumor † | 78.26% | 93.80% | |
| Central tumor | 65.80% | 70.92% | |
| Stage of NSCLC | All >0.05 | ||
| I | 69.22% | 81.70% | |
| II | 69.90% | 82.50% | |
| III | 71.50% | 79.10% | |
| IV | 70.90% | 82.70% |
The results were determined by using ROC curve analysis with optimum cutoffs.
Abbreviations: NSCLC, non–small-cell lung cancer; AC, adenocarcinoma; SC, squamous cell carcinoma.
†
Peripheral tumors were located at or within 1 cm of the visceral pleura.